IFRX
InflaRx N.V.
Price Chart
Latest Quote
$1.93
+0.00 (+0.00%)
Current Price
| Previous Close | $1.93 |
| Open | $1.93 |
| Day High | $2.02 |
| Day Low | $1.91 |
| Volume | 546,303 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 147.29M |
| Total Debt | $934K |
| Cash Equivalents | $45.15M |
| Revenue | $33K |
| Net Income | $-48.68M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $284.28M |
| EPS (TTM) | $-0.72 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $100.55M |
| Sales | $33K |
| Income | $-48.68M |
| Book/sh | $0.59 |
| Cash/sh | $0.27 |
| Employees | 65 |
Financial Ratios
| Quick Ratio | 3.64 |
| Current Ratio | 4.16 |
| Debt/Eq | 2.23 |
Returns & Margins
| ROA | -39.06% |
| ROE | -79.94% |
| Operating Margin | -144769.81% |
Ownership
| Insider Ownership | 2.95% |
| Institutional Ownership | 27.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.54 |
| P/S | 9691.97 |
| P/B | 3.30 |
Analyst Data
| Recommendation | none |
| Target Price | $7.73 |
Technical Indicators
| SMA20 | $1.93 |
| SMA50 | $2.01 |
| SMA200 | $1.34 |
| RSI | 43.30 |
| ATR | 0.1496 |
| Shares Float | 55.47M |
| Short Float | 5.07% |
| Short Ratio | 2.27 |
| Volatility | 2.44 |
| Rel Volume | 0.49 |
Performance History
| Week | +20.62% |
| Month | -26.05% |
| Quarter | +89.22% |
| 6 Months | +73.87% |
| YTD | +77.06% |
| Year | +143.38% |
| 3 Years | -58.49% |
| 5 Years | -39.12% |
| 10 Years | -87.13% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $1.93 | 546,400 |
| 2026-06-23 | $1.93 | 714,200 |
| 2026-06-22 | $1.90 | 793,600 |
| 2026-06-18 | $1.81 | 1,494,100 |
| 2026-06-17 | $1.82 | 1,977,000 |
| 2026-06-16 | $1.60 | 1,042,900 |
| 2026-06-15 | $1.62 | 974,800 |
| 2026-06-12 | $1.60 | 773,700 |
| 2026-06-11 | $1.68 | 613,900 |
| 2026-06-10 | $1.62 | 955,400 |
| 2026-06-09 | $1.66 | 2,133,300 |
| 2026-06-08 | $1.71 | 1,172,000 |
| 2026-06-05 | $1.84 | 1,634,600 |
| 2026-06-04 | $2.00 | 1,272,100 |
| 2026-06-03 | $2.06 | 1,410,200 |
| 2026-06-02 | $2.17 | 1,446,100 |
| 2026-06-01 | $2.28 | 903,200 |
| 2026-05-29 | $2.40 | 669,700 |
| 2026-05-28 | $2.38 | 899,600 |
| 2026-05-27 | $2.56 | 679,900 |
| 2026-05-26 | $2.74 | 1,644,700 |
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
đ° Latest News
What Do Analysts Say About InflaRx N.V. (IFRX)?
Insider Monkey âĸ 2026-06-10T18:22:42Z
Hereâs Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
Insider Monkey âĸ 2026-05-31T10:55:55Z
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
MarketBeat âĸ 2026-05-08T15:53:13Z
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
Insider Monkey âĸ 2026-05-07T17:28:49Z
April 2026 Penny Stocks To Watch For Potential Growth
Simply Wall St. âĸ 2026-04-16T18:05:22Z
Revance CEO Nadeem Moiz on Expansion, Opportunities & Capitalization
Exec Edge âĸ 2026-04-07T19:35:47Z
InflaRx N.V. (IFRX) Reports Q4 Loss, Lags Revenue Estimates
Zacks âĸ 2026-03-19T12:45:02Z
InflaRx Showcases Izicopan HS and CSU Data, Streamlines C5aR Strategy at Oppenheimer Conference
MarketBeat âĸ 2026-02-26T11:54:09Z
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
MarketBeat âĸ 2026-02-14T03:02:08Z
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
Simply Wall St. âĸ 2026-02-02T11:04:29Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $8,249,346 | $3,745,496 | $538,210 | $0 |
| Cost Of Revenue | $8,280,299 | $3,779,240 | $606,428 | $0 |
| Total Revenue | $33,418 | $188,890 | $71,880 | $0 |
| Operating Revenue | $33,418 | $188,890 | $71,880 | $0 |
| Expenses | ||||
| Interest Expense | $44,707 | $23,533 | $40,592 | $51,555 |
| Total Expenses | $55,014,591 | $60,466,412 | $50,880,650 | $36,729,940 |
| Other Income Expense | $-5,528,316 | $4,181,651 | $-2,098,521 | $2,782,610 |
| Net Non Operating Interest Income Expense | $8,531,022 | $3,618,729 | $4,294,405 | $354,287 |
| Total Other Finance Cost | $-6,473,156 | $-117,677 | $-356,887 | $287,651 |
| Interest Expense Non Operating | $44,707 | $23,533 | $40,592 | $51,555 |
| Operating Expense | $46,734,292 | $56,687,172 | $50,274,222 | $36,729,940 |
| Other Operating Expenses | $-3,029,735 | $-6,141,739 | $-15,413,585 | $-22,966,603 |
| Selling And Marketing Expense | $2,331,370 | $4,603,279 | $2,171,290 | $0 |
| General And Administrative Expense | $17,680,914 | $17,415,109 | $16,197,345 | $16,341,847 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
| Net Interest Income | $8,531,022 | $3,618,729 | $4,294,405 | $354,287 |
| Interest Income | $2,102,573 | $3,642,262 | $4,334,997 | $693,493 |
| Normalized Income | $-47,625,090 | $-55,786,589 | $-46,514,365 | $-36,375,651 |
| Net Income From Continuing And Discontinued Operation | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
| Total Operating Income As Reported | $-54,983,960 | $-60,395,199 | $-51,165,657 | $-36,729,939 |
| Net Income Common Stockholders | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
| Net Income | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
| Net Income Including Noncontrolling Interests | $-51,992,460 | $-52,483,086 | $-48,612,886 | $-33,593,042 |
| Net Income Continuous Operations | $-51,992,460 | $-52,483,086 | $-48,612,886 | $-33,593,042 |
| Pretax Income | $-51,978,467 | $-52,477,142 | $-48,612,886 | $-33,593,042 |
| Interest Income Non Operating | $2,102,573 | $3,642,262 | $4,334,997 | $693,493 |
| Operating Income | $-54,981,173 | $-60,277,522 | $-50,808,770 | $-36,729,940 |
| Depreciation Amortization Depletion Income Statement | $446,982 | $518,967 | $578,677 | $599,664 |
| Depreciation And Amortization In Income Statement | $446,982 | $518,967 | $578,677 | $599,664 |
| Gross Profit | $-8,246,881 | $-3,590,350 | $-534,548 | $0 |
| Per Share | ||||
| Diluted EPS | $-0.77 | $-0.89 | $-0.89 | $-0.76 |
| Basic EPS | $-0.77 | $-0.89 | $-0.89 | $-0.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,160,946 | $878,147 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-45,927,510 | $-56,082,550 | $-45,826,878 | $-35,644,369 |
| Total Unusual Items | $-5,528,316 | $4,181,651 | $-2,098,521 | $2,782,610 |
| Total Unusual Items Excluding Goodwill | $-5,528,316 | $4,181,651 | $-2,098,521 | $2,782,610 |
| Reconciled Depreciation | $477,934 | $552,711 | $646,895 | $679,728 |
| EBITDA (Bullshit earnings) | $-51,455,826 | $-51,900,898 | $-47,925,399 | $-32,861,759 |
| EBIT | $-51,933,760 | $-52,453,609 | $-48,572,294 | $-33,541,487 |
| Diluted Average Shares | $76,664,377 | $67,128,495 | $62,595,578 | $50,367,864 |
| Basic Average Shares | $76,664,377 | $67,128,495 | $62,595,578 | $50,367,864 |
| Diluted NI Availto Com Stockholders | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
| Tax Provision | $13,993 | $5,944 | $0 | $0 |
| Gain On Sale Of Security | $-5,528,316 | $4,181,651 | $-2,098,521 | $2,782,610 |
| Research And Development | $29,304,761 | $40,291,555 | $46,740,495 | $42,755,032 |
| Selling General And Administration | $20,012,284 | $22,018,389 | $18,368,635 | $16,341,847 |
| Other Gand A | $6,437,996 | $5,979,066 | $6,314,291 | $5,284,372 |
| Insurance And Claims | $1,060,333 | $1,789,157 | $2,204,489 | $2,655,377 |
| Salaries And Wages | $10,182,586 | $9,646,887 | $7,678,565 | $8,402,099 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $47,299,222 | $69,915,986 | $116,797,216 | $100,501,923 |
| Total Assets | $62,910,219 | $86,610,983 | $136,958,591 | $116,668,182 |
| Total Non Current Assets | $1,802,222 | $4,969,753 | $12,236,606 | $5,683,721 |
| Other Non Current Assets | $1 | $1 | - | $1 |
| Non Current Prepaid Assets | $172,266 | $232,691 | $293,115 | $350,992 |
| Investmentin Financial Assets | $270,449 | $3,523,174 | $10,314,164 | $3,305,118 |
| Goodwill And Other Intangible Assets | $48,143 | $57,857 | $78,407 | $158,260 |
| Other Intangible Assets | $48,143 | $57,857 | $78,407 | $158,260 |
| Current Assets | $61,107,997 | $81,641,230 | $124,721,984 | $110,984,461 |
| Other Current Assets | $2,965,237 | $5,926,109 | $106,510 | $2,907,680 |
| Prepaid Assets | $3,584,610 | $5,678,280 | $4,492,613 | $13,237,371 |
| Inventory | $0 | $7,858,797 | $12,951,814 | $0 |
| Receivables | $1,627,467 | $1,977,139 | $4,319,886 | $1,631,636 |
| Taxes Receivable | $1,627,467 | $1,977,139 | $4,319,886 | $1,631,636 |
| Cash Cash Equivalents And Short Term Investments | $52,930,683 | $60,200,904 | $102,851,161 | $93,207,774 |
| Cash And Cash Equivalents | $18,254,724 | $20,936,517 | $14,547,047 | $18,531,793 |
| Cash Equivalents | $16,800,197 | $16,074,374 | $5,857,299 | $3,899 |
| Cash Financial | $1,454,528 | $4,862,142 | $8,689,749 | $18,527,894 |
| Debt | ||||
| Total Debt | $1,023,033 | $917,268 | $1,276,114 | $1,545,725 |
| Long Term Debt And Capital Lease Obligation | $730,287 | $454,672 | $849,625 | $1,124,880 |
| Current Debt And Capital Lease Obligation | $292,746 | $462,595 | $426,489 | $420,845 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,562,853 | $16,637,141 | $20,082,969 | $16,007,999 |
| Total Non Current Liabilities Net Minority Interest | $772,303 | $496,688 | $891,641 | $1,166,895 |
| Other Non Current Liabilities | $42,015 | $42,015 | $42,015 | $42,015 |
| Current Liabilities | $14,790,551 | $16,140,453 | $19,191,328 | $14,841,103 |
| Other Current Liabilities | $7,019,575 | $343,563 | $3,287,879 | $168,176 |
| Payables And Accrued Expenses | $6,151,741 | $12,981,921 | $13,642,888 | $5,682,509 |
| Payables | $6,151,741 | $12,981,921 | $13,642,888 | $5,682,509 |
| Accounts Payable | $6,151,741 | $12,981,921 | $13,642,888 | $5,682,509 |
| Current Deferred Liabilities | - | - | $0 | $7,074,474 |
| Equity | ||||
| Common Stock Equity | $47,347,365 | $69,973,843 | $116,875,623 | $100,660,183 |
| Total Equity Gross Minority Interest | $47,347,365 | $69,973,842 | $116,875,622 | $100,660,183 |
| Stockholders Equity | $47,347,365 | $69,973,843 | $116,875,623 | $100,660,183 |
| Other Equity Interest | $8,170,650 | $8,477,282 | $8,410,808 | $8,268,294 |
| Gains Losses Not Affecting Retained Earnings | $55,326,993 | $50,263,031 | $45,630,687 | $41,740,418 |
| Other Equity Adjustments | $55,326,993 | $50,263,031 | $45,630,687 | $41,740,418 |
| Retained Earnings | $-430,472,843 | $-378,480,383 | $-325,997,298 | $-277,384,412 |
| Other | ||||
| Ordinary Shares Number | $82,366,254 | $67,621,866 | $67,088,155 | $50,932,852 |
| Share Issued | $82,366,254 | $67,621,866 | $67,088,155 | $50,932,852 |
| Tangible Book Value | $47,299,222 | $69,915,986 | $116,797,216 | $100,501,923 |
| Invested Capital | $47,347,365 | $69,973,843 | $116,875,623 | $100,660,183 |
| Working Capital | $46,317,446 | $65,500,777 | $105,530,656 | $96,143,358 |
| Capital Lease Obligations | $1,023,033 | $917,268 | $1,276,114 | $1,545,725 |
| Total Capitalization | $47,347,365 | $69,973,843 | $116,875,623 | $100,660,183 |
| Additional Paid In Capital | $404,438,615 | $381,599,290 | $380,780,847 | $321,923,941 |
| Capital Stock | $9,883,950 | $8,114,624 | $8,050,579 | $6,111,943 |
| Common Stock | $9,883,950 | $8,114,624 | $8,050,579 | $6,111,943 |
| Long Term Capital Lease Obligation | $730,287 | $454,672 | $849,625 | $1,124,880 |
| Current Capital Lease Obligation | $292,746 | $462,595 | $426,489 | $420,845 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,326,489 | $2,352,373 | $1,834,073 | $1,495,099 |
| Investments And Advances | $270,449 | $3,523,174 | $10,314,164 | $3,305,118 |
| Available For Sale Securities | $270,449 | $3,523,174 | $10,314,164 | - |
| Net PPE | $1,311,363 | $1,156,029 | $1,550,921 | $1,869,350 |
| Accumulated Depreciation | $-4,241,241 | $-3,930,022 | $-3,378,756 | $-2,867,817 |
| Gross PPE | $5,552,604 | $5,086,051 | $4,929,677 | $4,737,167 |
| Other Properties | $1,751,234 | $1,754,666 | $1,699,356 | $1,655,849 |
| Machinery Furniture Equipment | $276,561 | $276,561 | $198,398 | $142,566 |
| Buildings And Improvements | $3,524,808 | $3,054,824 | $3,031,922 | $2,938,751 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $0 | $64,517 | $376,082 | $0 |
| Work In Process | $0 | $7,700,755 | $12,093,152 | $0 |
| Raw Materials | $0 | $93,525 | $482,579 | $0 |
| Other Short Term Investments | $34,675,959 | $39,264,388 | $88,304,114 | $74,675,981 |
| Current Deferred Revenue | - | - | $0 | $7,074,474 |
| Held To Maturity Securities | - | - | $10,314,164 | $3,305,118 |
| Construction In Progress | - | - | $0 | $0 |
| Other Inventories | - | - | $1 | - |
| Current Accrued Expenses | - | - | - | $3,897,845 |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-40,366,894 | $-55,376,054 | $-43,174,282 | $-38,629,611 |
| Operating Activities | ||||
| Operating Cash Flow | $-40,235,079 | $-55,322,652 | $-43,081,881 | $-38,444,592 |
| Cash Flow From Continuing Operating Activities | $-40,235,078 | $-55,322,653 | $-43,081,880 | $-38,444,592 |
| Operating Gains Losses | $799,449 | $-42,271 | $470,567 | $439,056 |
| Investing Activities | ||||
| Capital Expenditure | $-131,815 | $-53,402 | $-92,401 | $-185,019 |
| Investing Cash Flow | $3,683,546 | $59,660,882 | $-20,162,489 | $22,055,481 |
| Cash Flow From Continuing Investing Activities | $3,683,547 | $59,660,880 | $-20,162,489 | $22,055,481 |
| Net Other Investing Changes | $-1 | $1 | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $26,091,890 | $1,251,326 | $64,354,484 | $2,677,024 |
| Financing Cash Flow | $37,959,037 | $440,294 | $60,369,455 | $2,207,427 |
| Cash Flow From Continuing Financing Activities | $37,959,039 | $440,294 | $60,369,455 | $2,207,427 |
| Net Other Financing Charges | $-2,441,074 | $-368,838 | $-3,828,901 | $-54,386 |
| Net Common Stock Issuance | $26,091,890 | $1,251,326 | $64,354,484 | $2,677,024 |
| Common Stock Issuance | $26,091,890 | $1,251,326 | $64,354,484 | $2,677,024 |
| Other | ||||
| Repayment Of Debt | $-407,409 | $-442,194 | $-426,088 | $-415,210 |
| End Cash Position | $18,254,724 | $20,936,515 | $14,547,047 | $18,531,794 |
| Beginning Cash Position | $20,936,515 | $14,547,047 | $18,531,794 | $29,907,709 |
| Effect Of Exchange Rate Changes | $-4,089,295 | $1,610,945 | $-1,109,831 | $2,805,767 |
| Changes In Cash | $1,407,504 | $4,778,524 | $-2,874,915 | $-14,181,682 |
| Proceeds From Stock Option Exercised | $14,715,631 | $0 | $269,959 | $0 |
| Net Issuance Payments Of Debt | $-407,409 | $-442,194 | $-426,088 | $-415,210 |
| Net Long Term Debt Issuance | $-407,409 | $-442,194 | $-426,088 | $-415,210 |
| Long Term Debt Payments | $-407,409 | $-442,194 | $-426,088 | $-415,210 |
| Net Investment Purchase And Sale | $3,815,362 | $59,714,283 | $-20,070,088 | $22,240,500 |
| Sale Of Investment | $56,339,364 | $99,978,733 | $98,480,641 | $95,699,022 |
| Purchase Of Investment | $-52,524,002 | $-40,264,451 | $-118,550,730 | $-73,458,523 |
| Net Intangibles Purchase And Sale | $-131,815 | $-53,402 | $-92,401 | $-185,019 |
| Purchase Of Intangibles | $-131,815 | $-53,402 | $-92,401 | $-185,019 |
| Interest Received Cfo | $1,980,400 | $2,555,767 | $1,973,663 | $1,466,560 |
| Interest Paid Cfo | $-39,278 | $-23,999 | $-41,045 | $-51,209 |
| Change In Working Capital | $5,532,780 | $-2,596,061 | $1,143,426 | $-11,135,374 |
| Change In Other Working Capital | $-1,025,885 | $518,300 | $338,975 | $-72,945 |
| Change In Other Current Liabilities | $65,410 | $-2,944,318 | $-3,954,771 | $-2,371,347 |
| Change In Other Current Assets | $5,464,638 | $-4,602,095 | $9,750,658 | $-4,604,599 |
| Change In Payables And Accrued Expense | $-6,830,180 | $-660,965 | $7,960,379 | $-4,086,483 |
| Change In Payable | $-6,830,180 | $-660,965 | $7,960,379 | $-4,086,483 |
| Change In Inventory | $7,858,797 | $5,093,017 | $-12,951,814 | $0 |
| Other Non Cash Items | $-2,057,867 | $-7,918,057 | $-2,552,771 | $-3,136,898 |
| Stock Based Compensation | $5,063,962 | $4,632,343 | $3,890,269 | $6,886,586 |
| Depreciation Amortization Depletion | $477,934 | $552,711 | $646,895 | $679,728 |
| Depreciation And Amortization | $477,934 | $552,711 | $646,895 | $679,728 |
| Amortization Cash Flow | $18,187 | $48,063 | $109,449 | $111,964 |
| Amortization Of Intangibles | $18,187 | $48,063 | $109,449 | $111,964 |
| Depreciation | $459,747 | $504,647 | $537,446 | $567,763 |
| Gain Loss On Investment Securities | $-6,475,943 | - | - | - |
| Net Foreign Currency Exchange Gain Loss | $7,275,392 | $-42,271 | $470,567 | $439,056 |
| Net Income From Continuing Operations | $-51,992,459 | $-52,483,085 | $-48,612,886 | $-33,593,041 |
Fetched: 2026-06-23